Geron Corp (GERN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.03 (-0.75%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Geron Corp (GERN)
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Key Insights

Critical company metrics and information
  • Share Price

    $3.93
  • Market Cap

    $2.38 Billion
  • Total Outstanding Shares

    604.50 Million Shares
  • Total Employees

    141
  • Dividend

    No dividend
  • IPO Date

    July 31, 1996
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.geron.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-215.61 Million
Net Cash Flow, Continuing$30.95 Million
Net Cash Flow From Financing Activities, Continuing$201.49 Million
Net Cash Flow From Investing Activities, Continuing$45.08 Million
Net Cash Flow From Operating Activities, Continuing$-215.61 Million
Net Cash Flow From Investing Activities$45.08 Million
Net Cash Flow$30.95 Million
Net Cash Flow From Financing Activities$201.49 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Earnings Per Share$0.32
Net Income/Loss Available To Common Stockholders, Basic$-201.19 Million
Income/Loss From Continuing Operations After Tax$-201.19 Million
Operating Income/Loss$-207.97 Million
Operating Expenses$237.45 Million
Income/Loss From Continuing Operations Before Tax$-146.47 Million
Costs And Expenses$232.44 Million
Net Income/Loss$-201.19 Million
Depreciation and Amortization$518000.00
Net Income/Loss Attributable To Parent$-201.19 Million
Diluted Earnings Per Share$0.32
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Benefits Costs and Expenses$175.96 Million
Basic Average Shares$1.30 Billion
Revenues$29.48 Million
Interest Expense, Operating$12.12 Million
Diluted Average Shares$1.30 Billion
Other Operating Expenses$182.34 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$398.06 Million
Fixed Assets$1.59 Million
Other Current Liabilities$109.02 Million
Equity$292.28 Million
Wages$15.18 Million
Liabilities And Equity$444.95 Million
Equity Attributable To Parent$292.28 Million
Current Liabilities$137.93 Million
Other Non-current Assets$45.30 Million
Equity Attributable To Noncontrolling Interest$0.00
Accounts Payable$13.73 Million
Other Current Assets$377.77 Million
Noncurrent Liabilities$14.73 Million
Liabilities$152.67 Million
Noncurrent Assets$46.89 Million
Assets$444.95 Million
Inventory$20.28 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.